Retrospective Study on Microbial Diversity in Paraffin Tissue of Pancreatic Diseases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age5-85
SponsorRuijin Hospital
About this trial
The great harm of pancreatic diseases and the unknown etiology and pathogenesis make it difficult to intervene in most early cases in time. Previous studies by scholars and applicants at home and abroad have shown that the microflora in pancreatic tissue is closely related to chronic pancreatitis and pancreatic cancer. However, the research on the mechanism of microbial diversity in pancreatic tissue and the occurrence and development of various pancreatic diseases has not been reported. Based on the previous research, this subject continues to take various pancreatic diseases as the research object based on the database of pancreatic center and pathology department of Ruijin Hospital Affiliated to Medical College of Shanghai Jiaotong University, To explore the characteristics of microbial flora in pancreas in different pancreatic diseases and its mechanism of influence on disease microenvironment. Select specific microbial flora or targets in the pancreas for various pancreatic diseases, so as to provide new theoretical basis and practical guidance for the early diagnosis and treatment of pancreatic diseases.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 5 years old, ≤ 85 years old;
After MDT discussion, routine surgery can be performed, and the postoperative pathology is clear as pancreatic cancer and other pancreatic diseases;
No history of antibiotics for three months before surgery, no history of yogurt containing probiotics
There is no serious damage to heart, liver and kidney function.
Disqualifiers
Antibiotics or yogurt containing probiotics history in three months;
Patients with evidence of sensory or motor neuropathy;
Those who have a clear cardiovascular disease, severe associated disease or active infection, including known HIV infection;
Those who have a history of other cancers.
Trial population
Male / Female, Age ≥ 5 years old, ≤ 85 years old; - After MDT discussion, routine surgery can be performed, and the postoperative pathology is clear as pancreatic cancer and other pancreatic diseases; - No history of antibiotics for three months before surgery, no history of yogurt containing probiotics - There is no serious damage to heart, liver and kidney function.
Trial design
Design model
Other
Time perspective
Retrospective
Treatments tested in this trial
No any intervention
Other interventionhave no any intervention
Treatment groups
800 Participants
are divided into 9 treatment groups9
Treatment groupsSee each treatment group below.
Group A: Pancreatic ductal adenocarcinoma1 intervention
Group B: Chronic pancreatitis1 intervention
Group C: Pancreatic serous cystadenoma1 intervention
Group D: Pancreatic mucinous cystadenoma1 intervention
Group E: Intraductal papillary mucinous tumor1 intervention
Group F: Pancreatic neuroendocrine tumor1 intervention
Group G: Pancreatic acinar cell carcinoma1 intervention
Group H: Solid pseudopapillary tumor of pancreas1 intervention
Group I: Blank paraffin section1 intervention
Trial outcomes
Primary outcomes
1
16sRNA and metagenomics
To obtain intestinal microbial information in patients with pancreatic cancer and other pancreatic diseases, to obtain microbial community structure, evolutionary relationship and information on microbial and environmental correlation in the intestinal environmental samples (weight unit: gram). The patient's microbiological characteristics were correlated with the patient's clinical characteristics and prognosis, so as to obtain the relevant biomarker information.
Time frame
7/2026Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov